US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
TSLA
$370.59
▲+0.00%
SDEV
$7.48
▲+0.00%
AMD
$633.91
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
TSLA
$370.59
▲+0.00%
SDEV
$7.48
▲+0.00%
AMD
$633.91
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Cellution Biologics
Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.
August 18, 2026
From
Cellution Biologics
Via
GlobeNewswire
Tickers
ELUT
Cellution Biologics Inc. Signs Definitive Agreement to Acquire SimpliDerm® Human Hydrated Acellular Dermal Matrix Business from Elutia Inc., Expanding its Allograft Portfolio
July 16, 2026
From
Cellution Biologics
Via
GlobeNewswire
Cellution Biologics Celebrates Expansion of U.S. Headquarters in Roswell, Georgia
May 05, 2026
From
Cellution Biologics
Via
GlobeNewswire
Cellution Biologics Inc. Announces Official Entry into the Ocular Market at ASCRS with the Launch of OptiCover™
April 07, 2026
From
Cellution Biologics
Via
GlobeNewswire
Cellution Biologics Inc. Announces First Peer-Reviewed Publication Demonstrating Positive Outcomes for AmchoPlast™ in the Treatment of Chronic Diabetic Foot Ulcers
December 16, 2025
From
Cellution Biologics
Via
GlobeNewswire
Cellution Biologics Inc. Announces U.S. Launch of AmnioPlast 1 and AmnioPlast Double for Ocular Surface Repair
November 19, 2025
From
Cellution Biologics
Via
GlobeNewswire